FDA inspection backlog overseas threatens new drug approvals

Inspections of overseas drug manufacturers came to a standstill during the height of the COVID-19 pandemic lockdown. Years later, the backlog of inspections is still high, adding to a host of risks across the pharma industry.

Roughly 2,000 pharma manufacturers haven’t been inspected by the FDA since before the pandemic, according to a recent analysis from the Associated Press.